Skip to main content

Table 2 Serum analytes significantly elevated in COPD

From: Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease

Analytea

 

Medianb

Fold (COPD/control)c

FDRd

  

BS

T54

Ctr1

Ctr2

BS/Ctr1

T54/Ctr1

BS/Ctr2

T54/Ctr2

 

COPD > Control

          

CD40 Ligand

ng/mL

2.50

0.96

0.01

0.01

250

95.9

250

95.9

< 10-8

EGF

pg/mL

699.49

230.99

14.84

3.70

47.1

15.6

189

62.4

< 10-8

BDNF

ng/mL

28.50

24.80

0.52

0.56

55.0

47.9

50.5

44.0

< 10-8

RANTES

ng/mL

18.65

15.90

1.28

1.22

14.5

12.4

15.2

13.0

< 10-8

Myeloperoxidase

ng/mL

2144.71

686.50

119.47

87.50

18.0

5.7

24.5

7.8

< 10-8

Eotaxin

pg/mL

232.50

162.50

20.50

20.50

11.3

7.9

11.3

7.9

< 10-8

EN-RAGE

ng/mL

254.97

35.60

13.40

14.50

19.0

2.7

17.6

2.5

< 10-8

Ferritin

ng/mL

166.00

113.00

18.95

28.00

8.8

6.0

5.9

4.0

< 10-8

IL-1RA

pg/mL

360.50

111.50

31.82

38.00

11.3

3.5

9.5

2.9

< 10-8

ENA-78

ng/mL

2.07

1.68

0.32

0.35

6.5

5.2

5.9

4.8

< 10-8

PAI-1

ng/mL

199.00

183.50

26.05

54.00

7.6

7.0

3.7

3.4

< 10-8

MCP-1

pg/mL

558.00

483.00

170.00

100.00

3.3

2.8

5.6

4.8

< 10-8

MIP-1beta

pg/mL

341.49

259.50

99.00

87.50

3.4

2.6

3.9

3.0

< 10-8

Thrombopoietin

ng/mL

4.92

4.70

1.62

1.60

3.0

2.9

3.1

2.9

< 10-8

TIMP-1

ng/mL

211.00

192.00

70.44

67.00

3.0

2.7

3.1

2.9

< 10-8

IL-16

pg/mL

1174.99

440.50

233.49

273.50

5.0

1.9

4.3

1.6

< 10-8

VEGF

pg/mL

1275.00

933.00

447.00

383.50

2.9

2.1

3.3

2.4

< 10-8

Cancer antigen 19-9

U/mL

7.19

5.94

2.11

3.30

3.4

2.8

2.2

1.8

3.7 × 10-7 - 4.5 × 10-4

CD40

ng/mL

1.84

1.06

0.61

0.59

3.0

1.7

3.1

1.8

< 10-8

Creatine kinase-MB

ng/mL

0.48

0.45

0.21

0.21

2.3

2.2

2.3

2.2

6.1 × 10-7 - 8.3 × 10-5

C-reactive protein

ug/mL

4.51

3.36

2.06

1.70

2.2

1.6

2.7

2.0

4.2 × 10-7 - 0.0074

Myoglobin

ng/mL

16.00

16.10

7.14

9.30

2.2

2.3

1.7

1.7

< 10-8 - 3.0 × 10-8

Stem cell factor

pg/mL

395.00

402.00

221.00

191.00

1.8

1.8

2.1

2.1

< 10-8

IL-18

pg/mL

302.49

253.50

148.00

154.50

2.0

1.7

2.0

1.6

< 10-8

TNF-RII

pg/mL

5.85

5.18

3.38

3.20

1.7

1.5

1.8

1.6

< 10-8

COPD < Control

          

IGF-1

ng/mL

45.30

29.30

188.55

203.00

-4.2

-6.4

-4.5

-6.9

3.0 × 10-7 - < 10-8

IgE

ng/mL

22.85

23.25

60.89

60.00

-2.7

-2.6

-2.6

-2.6

0.0043 - 6.0 × 10-6

  1. aMedian serum concentrations of the analytes in the indicated population: T54, C0168T54 COPD; BS, BioServe COPD; Ctr1, healthy control population 1; Ctr2, healthy control population 2.
  2. bSigned-fold = median in COPD/median in healthy control population. When median expression in COPD population was lower than in controls, the opposite of the reciprocal was reported.
  3. cFalse discovery rate (calculated from Mann-Whitney p-values) for each of the 4 COPD vs control comparisons expressed as the range of FDR values.
  4. dAnalytes significantly associated with COPD (FDR < 0.05 and |signed-fold| > 1.5) in each of the 4 comparisons are reported, ordered by descending average fold (COPD/control) values.
  5. BDNF, brain-derived neurotrophic factor; COPD, chronic obstructive pulmonary disease; EGF, epidermal growth factor; ENA, epithelial-derived neutrophil activating protein; EN-RAGE, extracellular newly identified-receptor for advanced glycation end-binding protein; FDR, false discovery rate; IgE, immunoglobulin E; IGF, insulin-like growth factor; IL, interleukin; -MB, -muscle/brain; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; PAI, plasminogen activating factor; RA, receptor agonist; RANTES, regulated upon activation, normally T-cell expressed, and secreted; TIMP, tissue inhibitor of metalloproteinases; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.